Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells

Haiming Dai, Husheng Ding, X. Wei Meng, Kevin L. Peterson, Paula A. Schneider, Judith E. Karp, Scott H Kaufmann

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Mitochondrial outer membrane permeabilization (MOMP), a key step in the intrinsic apoptotic pathway, is incompletely understood. Current models emphasize the role of BH3-only BCL2 family members in BAX and BAK activation. Here we demonstrate concentration-dependent BAK autoactivation under cell-free conditions and provide evidence that this autoactivation plays a key role in regulating the intrinsic apoptotic pathway in intact cells. In particular, we show that up to 80% of BAK (but not BAX) in lymphohematopoietic cell lines is oligomerized and bound to anti-apoptotic BCL2 family members in the absence of exogenous death stimuli. The extent of this constitutive BAK oligomerization is diminished by BAK knockdown and unaffected by BIM orPUMAdown-regulation. Further analysis indicates that sensitivity of cells to BH3 mimetics reflects the identity of the anti-apoptotic proteins to which BAK is constitutively bound, with extensive BCLXL•BAK complexes predicting navitoclax sensitivity, and extensive MCL1•BAK complexes predicting A1210477 sensitivity. Moreover, high BAK expression correlates with sensitivity of clinical acute myelogenous leukemia to chemotherapy, whereas low BAK levels correlate with resistance and relapse. Collectively, these results inform current understanding of MOMP and provide new insight into the ability of BH3 mimetics to induce apoptosis without directly activating BAX or BAK.

Original languageEnglish (US)
Pages (from-to)2140-2152
Number of pages13
JournalGenes and Development
Volume29
Issue number20
DOIs
StatePublished - Oct 15 2015

Fingerprint

Mitochondrial Membranes
Pharmaceutical Preparations
Apoptosis Regulatory Proteins
Aptitude
Acute Myeloid Leukemia
Apoptosis
Recurrence
Drug Therapy
Cell Line
navitoclax

Keywords

  • Apoptosis
  • BAK
  • BH3 mimetic

ASJC Scopus subject areas

  • Genetics
  • Developmental Biology

Cite this

Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells. / Dai, Haiming; Ding, Husheng; Meng, X. Wei; Peterson, Kevin L.; Schneider, Paula A.; Karp, Judith E.; Kaufmann, Scott H.

In: Genes and Development, Vol. 29, No. 20, 15.10.2015, p. 2140-2152.

Research output: Contribution to journalArticle

Dai, Haiming ; Ding, Husheng ; Meng, X. Wei ; Peterson, Kevin L. ; Schneider, Paula A. ; Karp, Judith E. ; Kaufmann, Scott H. / Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells. In: Genes and Development. 2015 ; Vol. 29, No. 20. pp. 2140-2152.
@article{fc31ea73d4d74ee197b5b1ee8b69e5df,
title = "Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells",
abstract = "Mitochondrial outer membrane permeabilization (MOMP), a key step in the intrinsic apoptotic pathway, is incompletely understood. Current models emphasize the role of BH3-only BCL2 family members in BAX and BAK activation. Here we demonstrate concentration-dependent BAK autoactivation under cell-free conditions and provide evidence that this autoactivation plays a key role in regulating the intrinsic apoptotic pathway in intact cells. In particular, we show that up to 80{\%} of BAK (but not BAX) in lymphohematopoietic cell lines is oligomerized and bound to anti-apoptotic BCL2 family members in the absence of exogenous death stimuli. The extent of this constitutive BAK oligomerization is diminished by BAK knockdown and unaffected by BIM orPUMAdown-regulation. Further analysis indicates that sensitivity of cells to BH3 mimetics reflects the identity of the anti-apoptotic proteins to which BAK is constitutively bound, with extensive BCLXL•BAK complexes predicting navitoclax sensitivity, and extensive MCL1•BAK complexes predicting A1210477 sensitivity. Moreover, high BAK expression correlates with sensitivity of clinical acute myelogenous leukemia to chemotherapy, whereas low BAK levels correlate with resistance and relapse. Collectively, these results inform current understanding of MOMP and provide new insight into the ability of BH3 mimetics to induce apoptosis without directly activating BAX or BAK.",
keywords = "Apoptosis, BAK, BH3 mimetic",
author = "Haiming Dai and Husheng Ding and Meng, {X. Wei} and Peterson, {Kevin L.} and Schneider, {Paula A.} and Karp, {Judith E.} and Kaufmann, {Scott H}",
year = "2015",
month = "10",
day = "15",
doi = "10.1101/gad.267997.115",
language = "English (US)",
volume = "29",
pages = "2140--2152",
journal = "Genes and Development",
issn = "0890-9369",
publisher = "Cold Spring Harbor Laboratory Press",
number = "20",

}

TY - JOUR

T1 - Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells

AU - Dai, Haiming

AU - Ding, Husheng

AU - Meng, X. Wei

AU - Peterson, Kevin L.

AU - Schneider, Paula A.

AU - Karp, Judith E.

AU - Kaufmann, Scott H

PY - 2015/10/15

Y1 - 2015/10/15

N2 - Mitochondrial outer membrane permeabilization (MOMP), a key step in the intrinsic apoptotic pathway, is incompletely understood. Current models emphasize the role of BH3-only BCL2 family members in BAX and BAK activation. Here we demonstrate concentration-dependent BAK autoactivation under cell-free conditions and provide evidence that this autoactivation plays a key role in regulating the intrinsic apoptotic pathway in intact cells. In particular, we show that up to 80% of BAK (but not BAX) in lymphohematopoietic cell lines is oligomerized and bound to anti-apoptotic BCL2 family members in the absence of exogenous death stimuli. The extent of this constitutive BAK oligomerization is diminished by BAK knockdown and unaffected by BIM orPUMAdown-regulation. Further analysis indicates that sensitivity of cells to BH3 mimetics reflects the identity of the anti-apoptotic proteins to which BAK is constitutively bound, with extensive BCLXL•BAK complexes predicting navitoclax sensitivity, and extensive MCL1•BAK complexes predicting A1210477 sensitivity. Moreover, high BAK expression correlates with sensitivity of clinical acute myelogenous leukemia to chemotherapy, whereas low BAK levels correlate with resistance and relapse. Collectively, these results inform current understanding of MOMP and provide new insight into the ability of BH3 mimetics to induce apoptosis without directly activating BAX or BAK.

AB - Mitochondrial outer membrane permeabilization (MOMP), a key step in the intrinsic apoptotic pathway, is incompletely understood. Current models emphasize the role of BH3-only BCL2 family members in BAX and BAK activation. Here we demonstrate concentration-dependent BAK autoactivation under cell-free conditions and provide evidence that this autoactivation plays a key role in regulating the intrinsic apoptotic pathway in intact cells. In particular, we show that up to 80% of BAK (but not BAX) in lymphohematopoietic cell lines is oligomerized and bound to anti-apoptotic BCL2 family members in the absence of exogenous death stimuli. The extent of this constitutive BAK oligomerization is diminished by BAK knockdown and unaffected by BIM orPUMAdown-regulation. Further analysis indicates that sensitivity of cells to BH3 mimetics reflects the identity of the anti-apoptotic proteins to which BAK is constitutively bound, with extensive BCLXL•BAK complexes predicting navitoclax sensitivity, and extensive MCL1•BAK complexes predicting A1210477 sensitivity. Moreover, high BAK expression correlates with sensitivity of clinical acute myelogenous leukemia to chemotherapy, whereas low BAK levels correlate with resistance and relapse. Collectively, these results inform current understanding of MOMP and provide new insight into the ability of BH3 mimetics to induce apoptosis without directly activating BAX or BAK.

KW - Apoptosis

KW - BAK

KW - BH3 mimetic

UR - http://www.scopus.com/inward/record.url?scp=84944729445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944729445&partnerID=8YFLogxK

U2 - 10.1101/gad.267997.115

DO - 10.1101/gad.267997.115

M3 - Article

C2 - 26494789

AN - SCOPUS:84944729445

VL - 29

SP - 2140

EP - 2152

JO - Genes and Development

JF - Genes and Development

SN - 0890-9369

IS - 20

ER -